Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Conditions
Brief summary
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy
Detailed description
PRIMARY OBJECTIVES: I. To evaluate progression-free survival (PFS) achieved with STA-9090 (Hsp90 inhibitor STA-9090) in men with castration-resistant prostate cancer (CRPC) who have received prior docetaxel based therapy. SECONDARY OBJECTIVES: I. To assess the percentage change in prostate-specific antigen (PSA) from baseline to 12 weeks. II. To assess overall safety and tolerability of STA-9090. III. To evaluate overall survival (OS) outcome in metastatic CRPC who have received prior docetaxel therapy. IV. To investigate the association of progression-free survival (PFS) and PSA response rate with primary and secondary target markers. TERTIARY OBJECTIVES: I. To evaluate potential markers for predicting drug response or efficacy, blood samples will be used to collect the serum and extract messenger ribonucleic acid (mRNA) from mononuclear cells and analyzed by quantitative real-time polymerase chain reaction (PCR) and/or enzyme-linked immunosorbent assay (ELISA). OUTLINE: Patients receive Hsp90 inhibitor STA-9090 intravenously (IV) over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 4 weeks.
Interventions
DRUGHsp90 inhibitor STA-9090
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
GENETICpolymerase chain reaction
Correlative studies
OTHERenzyme-linked immunosorbent assay
Correlative studies
GENETICRNA analysis
Correlative studies
OTHERspectrophotometry
Correlative studies
GENETICreverse transcriptase-polymerase chain reaction
Correlative studies
GENETICgene expression analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed diagnosis of prostate adenocarcinoma with metastasis and objective progression or rising PSA despite androgen deprivation therapy and antiandrogen withdrawal when applicable * Progression after docetaxel based chemotherapy is needed as follows: * a) If measurable disease present, then either rising PSA, increase in size of the lesion/s or both should be present * b) Patients with rising PSA only as progression must demonstrate a rising trend with 2 successive elevations at minimum intervals of 1 week; a minimum PSA of 5 ng/ml, or new areas of bony metastases on bone scan are required for patients with no measurable disease; no minimum PSA requirement for patients with measurable disease * Patients should have received at least one prior docetaxel based regimen for metastatic disease; no maximum prior therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 * Life expectancy of at least 3 months * Prior radiation therapy or chemotherapy completed at least 28 days prior to enrollment * All patients must be documented to be castrate with a testosterone level =\< 0.5 ng/ml; luteinizing-hormone-releasing hormone (LHRH) agonist therapy must be continued, if required to maintain castrate levels of testosterone; patients must be off antiandrogens for a minimum of 4 weeks for flutamide and 6 weeks for bicalutamide or nilutamide * Absolute neutrophil count \>= 1,500 cells/uL * Platelets \>= 100,000/uL * Hemoglobin \>= 9.0 g/dL * Serum creatinine =\< 1.5 x upper limit of normal (ULN); Note: if serum creatinine is \> 1.5 x ULN, subject is eligible if the calculated creatinine clearance (CLcr) is \>= 50 mL/min * Total bilirubin =\< 1.5 x ULN * For patients without documented bone metastases or for patients with liver metastases: transaminases (aspartate aminotransferase \[AST\]/serum glutamic oxaloacetic transaminase \[SGOT\] and/or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase \[SGPT\]) may be up to 2.5 x institutional ULN if alkaline phosphatase is =\< ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are =\< ULN * For patients with documented bone metastases, the transaminases (AST/SGOT and/or ALT/SGPT) should be less than 2.5 x institutional ULN, without regard to the alkaline phosphatase level * Sexually active males must use measures to prevent pregnancy in their partners while on STA-9090 * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures * Ability to understand and willingness to sign a written informed consent document
Exclusion criteria
* Major surgery within 4 weeks prior to first dose of STA-9090 * Poor venous access for study drug administration or would require a peripheral or central indwelling catheter for study drug administration; study drug administration via indwelling catheters is prohibited at this time * Use of any chemotherapy or other standard systemic treatments for prostate cancer, including investigational agents within 2 weeks or 6 half- lives of the agent, whichever is shorter, prior to receiving STA-9090; there must be at least 2 weeks between the end of palliative radiation and the start of study drug and all radiation therapy (XRT)-associated toxicities resolved to Grade 1 or 0 * History of severe allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol \[PEG\] 300 and Polysorbate 80 \[i.e. docetaxel\]) * Baseline QTc \> 450 msec or previous history of QT prolongation while taking other medications * Ventricular ejection fraction (Ef) =\< 55% at baseline * Any history of current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery * History of current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block * New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers or diuretics * Current or prior radiation therapy to the left hemithorax * Treatment with chronic immunosuppressants (e.g. cyclosporine following transplantation) * Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy | At 6 months | Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage Change in PSA | From baseline to 12 weeks | Percentage change in PSA from baseline. |
| Overall Safety and Tolerability of STA-9090 | Day 1, 8, and 15 of each course and at end of treatment | Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events |
| OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy | From first dose to death or the date last known alive | Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method |
| Association of PFS With PSA | At 6 months | Association of PFS with PSA using Cox PH regression model |
| Potential Markers for Predicting Drug Response or Efficacy | At baseline, day 1 of course 3, and end of treatment | Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Hsp90 inhibitor STA-9090: Given IV
laboratory biomarker analysis: Correlative studies
polymerase chain reaction: Correlative studies
enzyme-linked immunosorbent assay: Correlative studies
RNA analysis: Correlative studies
spectrophotometry: Correlative studies
reverse transcriptase-polymerase chain reaction: Correlative studies
gene expression analysis: Correlative studies | 18 |
| Total | 18 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Never rec'd treatment, but registered. | 1 |
Baseline characteristics
| Characteristic | Treatment (Enzyme Inhibitor Therapy) |
|---|---|
| Age, Continuous | 68 years |
| Region of Enrollment United States | 18 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 17 / 18 |
| serious Total, serious adverse events | 10 / 18 |
Outcome results
Primary
PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy
Our primary objective was to determine the 6-month PFS rate by using a binary (yes/no) endpoint of 6 months of PFS. Treatment success was defined as achievement of at least 6 months of PFS. Patients who did not complete 6 months of ganetespib therapy for any reason (including death from any cause) were considered treatment failures and were recorded as not achieving the primary endpoint.
Time frame: At 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy | 0.0 proportion with 6+ months PFS |
Secondary
Association of PFS With PSA
Association of PFS with PSA using Cox PH regression model
Time frame: At 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | Association of PFS With PSA | 1.000 Hazard Ratio |
Secondary
OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy
Overall Survival (OS) in metastatic Castrate Resistant Prostate Cancer (CRPC) who have received prior docetaxel therapy using Kaplan-Meier method
Time frame: From first dose to death or the date last known alive
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | OS in Metastatic CRPC Who Have Received Prior Docetaxel Therapy | 12.5 months |
Secondary
Overall Safety and Tolerability of STA-9090
Overall safety and tolerability of STA-9090 by total number of grade 3 adverse events
Time frame: Day 1, 8, and 15 of each course and at end of treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | Overall Safety and Tolerability of STA-9090 | 35 events of grade 3+ toxicity |
Secondary
Percentage Change in PSA
Percentage change in PSA from baseline.
Time frame: From baseline to 12 weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Enzyme Inhibitor Therapy) | Percentage Change in PSA | 78.65 percentage change from baseline PSA |
Secondary
Potential Markers for Predicting Drug Response or Efficacy
Potential markers for predicting drug response or efficacy : This is not a measurable outcome, but a possible entity for further study.
Time frame: At baseline, day 1 of course 3, and end of treatment
Population: No data was collected for this outcome.